Advertisement
Advertisement
CTNM
Contineum Therapeutics, Inc. Class A Common Stock
12.51
USDSponsored
-0.89
-6.64%
Sep 23, 16:00 UTC -4
Closed
After-Market
12.53
+0.02
+0.12%
CTNM Earnings Reports
Positive Surprise Ratio
CTNM beat 4 of 10 last estimates.
40%
Next Report
Date of Next Report
Oct 28, 2026
Estimate for Q3 26 (Revenue/ EPS)
--
/-$0.46
Implied change from Q2 26 (Revenue/ EPS)
--
/+15.00%
Implied change from Q3 25 (Revenue/ EPS)
--
/+2.22%
Contineum Therapeutics, Inc. Class A Common Stock earnings per share and revenue
On Jul 30, 2026, CTNM reported earnings of -0.40 USD per share (EPS) for Q2 26, beating the estimate of -0.46 USD, resulting in a 13.18% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +3.82% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 6 analysts forecast an EPS of -0.46 USD, with revenue projected to reach -- USD, implying an increase of 15.00% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
AnaptysBio, Inc. Common Stock
Report Date
Sep 21, 2026 For Q2 26
Estimate
$0.00
Actual
$5.11
Surprise
>+10,000.00%
BlossomHill Therapeutics, Inc. Common Stock
Report Date
Sep 18, 2026 For Q2 26
Estimate
-$1.03
Actual
-$8.75
Surprise
-746.56%
Vogenx Inc Common Stock
Report Date
Sep 17, 2026 For Q2 26
Estimate
-$0.07
Actual
-$0.07
Surprise
+1.96%
Benitec Biopharma Inc. Common Stock
Report Date
Sep 14, 2026 For Q4 26
Estimate
-$0.27
Actual
-$0.26
Surprise
+5.59%
Anixa Biosciences, Inc.
Report Date
Sep 09, 2026 For Q3 26
Estimate
-$0.08
Actual
-$0.08
Surprise
+8.78%
Abivax SA - ADR
Report Date
Sep 21, 2026 For Q2 26
Estimate
-$1.82
Actual
-$2.09
Surprise
-14.47%
AYTU BioPharma, Inc. Common Stock
Report Date
Sep 22, 2026 For Q4 26
Estimate
-$0.33
Actual
-$0.05
Surprise
+84.92%
Neuphoria Therapeutics Inc. Common Stock
Report Date
Sep 18, 2026 For Q4 26
Estimate
-$0.57
Actual
-$0.95
Surprise
-66.32%
NewcelX Ltd. Ordinary Shares
Report Date
Sep 18, 2026 For Q2 26
Estimate
-$0.54
Actual
-$0.96
Surprise
-77.58%
Alzamend Neuro, Inc. Common Stock
Report Date
Sep 10, 2026 For Q1 27
Estimate
-$0.57
Actual
-$0.68
Surprise
-19.05%
FAQ
What were Contineum Therapeutics, Inc. Class A Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Contineum Therapeutics, Inc. Class A Common Stock reported EPS of -$0.40, beating estimates by 13.18%, and revenue of $0.00, 0% as expectations.
How did the market react to Contineum Therapeutics, Inc. Class A Common Stock's Q2 2026 earnings?
The stock price moved up 3.82%, changed from $14.39 before the earnings release to $14.94 the day after.
When is Contineum Therapeutics, Inc. Class A Common Stock expected to report next?
The next earning report is scheduled for Oct 28, 2026.
What are the forecasts for Contineum Therapeutics, Inc. Class A Common Stock's next earnings report?
Based on 6
analysts, Contineum Therapeutics, Inc. Class A Common Stock is expected to report EPS of -$0.46 and revenue of -- for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.